Reducing the global burden of HTLV-1 infection: An agenda for research and action.
Antiviral Res
; 137: 41-48, 2017 01.
Article
en En
| MEDLINE
| ID: mdl-27840202
ABSTRACT
Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Infecciones por HTLV-I
/
Salud Global
/
Investigación Biomédica
Tipo de estudio:
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Antiviral Res
Año:
2017
Tipo del documento:
Article